ATON Partners

Investment decisions are made by co-founders Patrick Sullivan and Daniel Levangie, who share a decades-long track record operating and investing in medical-device companies. Both have led companies from concept-stage technology development through to profitable exits, most notably during their joint tenure at Cytyc Corporation and with the Bloodhound hematology platform.

ATON sources opportunities through the co-founders’ individual networks built across twenty-plus years of medical-device and diagnostics operating experience. The firm’s hybrid model — offering management advisory services to early-stage companies — creates a proprietary pipeline where consulting engagements can convert into direct investment opportunities.

ATON targets early-stage companies, placing capital at the concept and early-commercialization phases of development before clinical or scale validation. The approach reflects the co-founders’ operating playbook of guiding immature technologies through regulatory approval and market adoption, as they did with Cytyc’s ThinPrep Pap Test and with Roche-acquired Bloodhound.